Clinical Trials Logo

Plaque Psoriasis Vulgaris clinical trials

View clinical trials related to Plaque Psoriasis Vulgaris.

Filter by:
  • None
  • Page 1

NCT ID: NCT03310320 Terminated - Clinical trials for Plaque Psoriasis Vulgaris

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis

DERMIS
Start date: November 29, 2017
Phase: Phase 1
Study type: Interventional

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated. The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.

NCT ID: NCT03029741 Completed - Clinical trials for Plaque Psoriasis Vulgaris

Bioavailability of AZD0284 and IV Microtracer Study

Start date: February 21, 2017
Phase: Phase 1
Study type: Interventional

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. It occurs when skin cells are replaced more quickly than usual. The seriousness of psoriasis varies greatly from person to person. For some people it is a minor irritation, but for others it can have a major impact on their quality of life. . The purpose of the study is to determine how much of AZD0284 is taken up by the body. The safety and tolerability of the drug will also be assessed. It is hoped that the study drug will improve the management of psoriasis.

NCT ID: NCT02976831 Completed - Clinical trials for Plaque Psoriasis Vulgaris

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Start date: December 9, 2016
Phase: Phase 1
Study type: Interventional

Plaque psoriasis vulgaris is a chronic inflammatory skin disorder, affecting 1-3% of the population in Europe and the United States of America (USA) and represents one of the most prevalent immune inflammatory diseases. AZD0284 is a potent selective inverse agonist of RORg, which is being developed for the management of psoriasis. The current Phase 1 study investigates the safety, tolerability, food effect, pharmacokinetic (PK) and pharmacodynamic (PD) properties of single and repeated doses of AZD0284. The study will be conducted in healthy subjects. The study will be divided into 2 parts: Part 1 (SAD) and Part 2 (MAD), with Part 1 being split into 2 sub-parts: 1A (fasting) and 1B (fed). The results from this study will form the basis for decisions on future studies. The study will help to identify appropriate, well-tolerated doses that can be administered in subsequent studies in patients with psoriasis.